Acute myeloid leukemia (AML) is an immunophenotypically heterogenous malignant disease, in which CD34 positivity has been significantly correlated with a lower complete response (CR) rate, drug resistance and poor outcome [1-3]. The gene discussed is CD34; the disease is acute myeloid leukemia.